Company Update (NYSE:BMY): FDA expands lung cancer approval for Bristol-Myers’ drug

[Reuters] – The U.S. Food and Drug Administration on Friday expanded its approval of Bristol-Myers Squibb Co’s immunotherapy drug Opdivo for patients with an additional form of advanced lung cancer. The agency said . . . → Read More: Company Update (NYSE:BMY): FDA expands lung cancer approval for Bristol-Myers’ drug Similar Articles: Stock Update (NYSE:BMY): FDA approves Bristol Myers’ combination treatment for skin cancer Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – CORRECTING and REPLACING Bristol-Myers Squibb to Announce Results for Third Quarter 2015 on October 27 Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – New Cohorts from CheckMate -012 Assess Optimal Dosing of Opdivo+Yervoy in the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer